✦ LIBER ✦

Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

✍ Scribed by Michael J. Overman; Syed M. Kazmi; Jagriti Jhamb; E Lin; James C. Yao; James L. Abbruzzese; Linus Ho; Jaffer Ajani; Alexandria Phan

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 140 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24925

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly 5-fluorouracil plus cisplatin for

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

✍ Young Joo Lee; Chang Geol Lee; Byoung Chul Cho; Gwi Eon Kim; Hye Jin Choi; Eun C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

## Abstract ## Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5‐fluorouracil (5‐FU) and cisplatin has increased acute toxicities as well as survival. Once‐weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we

Optimizing docetaxel chemotherapy in pat

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction : Evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen

✍ Jaffer A. Ajani 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB

A randomized phase 2 study of docetaxel

A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

✍ Hei-Cheul Jeung; Sun Young Rha; Chong Kun Im; Sang Joon Shin; Joong Bae Ahn; Woo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

Docetaxel, cisplatin, and 5-fluorouracil

Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck : The Dana Farber Cancer Institute experience

✍ Robert Haddad; A. Dimitrios Colevas; Roy Tishler; Paul Busse; Laura Goguen; Chri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract ## BACKGROUND The authors conducted a series of four Phase I–II trials of high‐dose and intermediate‐dose docetaxel, cisplatin, and 5‐fluorouracil (TPF)‐based induction chemotherapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). The chemotherapy regime

An open-label, multinational, multicente

An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 study

✍ Jaffer A. Ajani; J. Randolph Hecht; Linus Ho; Jackie Baker; Marga Oortgiesen; Ar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB

Ten-year follow-up of a phase 2 study of

Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer

✍ Gisele A. Sarosy; Mahrukh M. Hussain; Michael V. Seiden; Arlan F. Fuller; Najmos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND: The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced‐stage epithelial ovarian cancer (EOC) who were receiving dose‐intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing sched